Multiple Myeloma: DNA Translocation Creates Drug Resistance, Worsens Prognosis

​A new study reports that for patients with multiple myeloma, DNA translocation involving the immunoglobulin lambda (IgL) locus predicts poor outcomes and resistance to immunomodulatory imide drug (IMiD) therapies such as lenalidomide. The second most common hematological cancer, multiple myeloma has seen substantial increases in survival in recent years, thanks to a variety of new therapies. However, around 20% of patients still relapse or die within two years of diagnosis. Of these high-risk p...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.